- ISIN
- US00972G1085
- CUSIP
- 00972G108
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Sep 21, 2015
Highlights
- Market Cap
- $16.67M
- Enterprise Value
- $15.37M
- EPS (TTM)
- -$31.73
- EBITDA (TTM)
- -$29.46M
- Year Range
- $3.02 - $49.60
- Target Price
- $1,200.00
- ROA (TTM)
- -82.76%
- ROE (TTM)
- -195.05%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
AKTX Performance Chart
Akari Therapeutics, Plc (AKTX) is down 2.9% since the beginning of the year. At $11 per share, AKTX is trading 77.4% below its 52-week high of $50. Investors who bought $1,000 worth of AKTX shares 5 years ago would now be looking at an investment worth $8.
Loading charts...
Returns By Period
Akari Therapeutics, Plc (AKTX) has returned -2.85% so far this year and -74.93% over the past 12 months. Over the last ten years, AKTX has returned -49.66% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.
Akari Therapeutics, Plc
- 1D
- 2.65%
- 1M
- -38.53%
- YTD
- -2.85%
- 6M
- 6.34%
- 1Y
- -74.93%
- 3Y*
- -55.68%
- 5Y*
- -61.64%
- 10Y*
- -49.66%
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
AKTX Monthly Returns History
Based on dividend-adjusted daily data since Sep 21, 2015, AKTX's average daily return is -0.02%, while the average monthly return is -2.00%.
Historically, 38% of months were positive and 62% were negative. The best month was May 2026 with a return of +204.3%, while the worst month was May 2017 at -59.1%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 8 months.
On a daily basis, AKTX closed higher 42% of trading days. The best single day was May 22, 2026 with a return of +255.5%, while the worst single day was May 12, 2026 at -40.6%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -18.82% | 0.68% | -45.49% | 4.86% | 204.25% | -31.65% | -2.85% | ||||||
| 2025 | -10.66% | -20.18% | 42.53% | 16.13% | -6.25% | -13.34% | -11.96% | -26.21% | 32.89% | -25.74% | -35.15% | -40.58% | -76.31% |
| 2024 | -16.03% | -10.31% | -20.64% | -17.43% | 11.30% | 57.53% | 43.33% | -1.03% | -22.98% | -18.64% | -49.58% | 0.83% | -60.90% |
| 2023 | -0.66% | -26.09% | -47.33% | -0.33% | -2.32% | -3.90% | 46.82% | -36.90% | 25.40% | -13.67% | -13.49% | 5.76% | -66.80% |
| 2022 | -8.67% | -1.46% | -11.11% | -0.83% | -1.68% | -14.54% | 14.01% | 4.39% | -47.06% | -26.06% | 18.63% | -14.97% | -68.67% |
| 2021 | 36.76% | 32.41% | -21.19% | -21.97% | -12.86% | -3.62% | -6.36% | 13.58% | -11.41% | 1.84% | -1.81% | -7.98% | -18.92% |
Benchmark Metrics
Akari Therapeutics, Plc has an annualized alpha of -12.31%, beta of 0.58, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since September 21, 2015.
- This stock participated in 215.57% of S&P 500 Index downside but only -55.07% of its upside - more exposed to losses than it benefited from rallies.
- Beta of 0.58 may look defensive, but with R2 of 0.01 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -12.31%
- Beta
- 0.58
- R²
- 0.01
- Upside Capture
- -55.07%
- Downside Capture
- 215.57%
Return for Risk
Risk / Return Rank
AKTX ranks 33 for risk / return — below 33% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Akari Therapeutics, Plc (AKTX) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| AKTX | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.29 | ||
| Sortino ratioReturn per unit of downside risk | -1.87 | ||
| Omega ratioGain probability vs. loss probability | 1.12 | 1.37 | -0.25 |
| Calmar ratioReturn relative to maximum drawdown | -0.80 | 2.78 | -3.59 |
| Martin ratioReturn relative to average drawdown | -1.19 | 12.44 | -13.63 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Akari Therapeutics, Plc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Akari Therapeutics, Plc was 99.99%, occurring on May 12, 2026. The portfolio has not yet recovered.
The current Akari Therapeutics, Plc drawdown is 99.96%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -99.99%May 2026 | 10y 7mo | — | 10y 9moSep 2015 - now |
Drawdown Indicators
| AKTX | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.99% | -56.78% | -43.21% |
Max Drawdown (1Y)Largest decline over 1 year | -93.46% | -9.10% | -84.36% |
Max Drawdown (3Y)Largest decline over 3 years | -98.57% | -18.90% | -79.67% |
Max Drawdown (5Y)Largest decline over 5 years | -99.80% | -25.43% | -74.37% |
Max Drawdown (10Y)Largest decline over 10 years | -99.98% | -33.92% | -66.06% |
Current DrawdownCurrent decline from peak | -99.96% | -1.80% | -98.16% |
Average DrawdownAverage peak-to-trough decline | -91.10% | -10.71% | -80.39% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 62.78% | 2.03% | +60.75% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Akari Therapeutics, Plc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Akari Therapeutics, Plc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for AKTX in comparison with other companies in the Biotechnology industry. Currently, AKTX has a P/B value of 1.2. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with AKTX
Add Akari Therapeutics, Plc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with AKTX